Table 2.
PK of tegaserod in fasting and fed conditions.
| Treatment | Pharmacokinetic Parameters (mean ± SD, median for tmax and tlag) | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Cmax (ng/mL) |
AUC 0-∞ (ng*h/m) |
tmax (h) |
t1/2,z (h) |
tlag (h) |
CL/F (L*h-1) |
Vz/F (L) |
Vss (L) |
F (%) | ||
| 12 mg p.o. | fasted | 5.5 ± 2.2 | 17.1 ± 6.4 | 1.5 | 6.5 ± 3.2 | 0 | 799 ± 301 | 7350 ± 6147 | - | 11 ±4 |
| 12 mg p.o. | fed | 2.5 ± 0.9 | 8.0 ± 2.6 | 2 | 7.2 ± 2.3 | 0.7 | 1995 ± 548 | 11821 ±1984 | - | - |
| 3 mg infusion§ |
fasted | 45.4 ± 9.2 | 40.0 ± 7.9 | - | 10.8 ± 4.6 | - | 77 ± 15* | 1149 ± 405* | 368 ±223 | - |
*F=1; § over 40 min. Data are referred to a study involving 12 healthy male subjects aged 19-31 years [116].